Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension.

A new interesting article has been published in Nat Commun. 2019 May 17;10(1):2204. doi: 10.1038/s41467-019-10135-x. Research Support, Non-U.S. Gov’t and titled:

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension.

Authors of this article are:

Weiss A,, Neubauer MC,, Yerabolu D,, Kojonazarov B,, Schlueter BC,, Neubert L, Jonigk D, Baal N,, Ruppert C,, Dorfmuller P, Pullamsetti SS,, Weissmann N,, Ghofrani HA, Grimminger F, Seeger W, Schermuly RT,.

A summary of the article is shown below:

Pulmonary arterial hypertension (PAH) is a devastating disease with poor prognosis and limited therapeutic options. We screened for pathways that may be responsible for the abnormal phenotype of pulmonary arterial smooth muscle cells (PASMCs), a major contributor of PAH pathobiology, and identified cyclin-dependent kinases (CDKs) as overactivated kinases in specimens derived from patients with idiopathic PAH. This increased CDK activity is confirmed at the level of mRNA and protein expression in human and experimental PAH, respectively. Specific CDK inhibition by dinaciclib and palbociclib decreases PASMC proliferation via cell cycle arrest and interference with the downstream CDK-Rb (retinoblastoma protein)-E2F signaling pathway. In two experimental models of PAH (i.e., monocrotaline and Su5416/hypoxia treated rats) palbociclib reverses the elevated right ventricular systolic pressure, reduces right heart hypertrophy, restores the cardiac index, and reduces pulmonary vascular remodeling. These results demonstrate that inhibition of CDKs by palbociclib may be a therapeutic strategy in PAH.

Check out the article’s website on Pubmed for more information:

This article is a good source of information and a good way to become familiar with topics such as: n/a.

Molecular Depot

Your specialty peptide, proteins, antibodies and chemical compounds store.